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Available online xxxxCombined small cell lung cancer (cSCLC) is relatively unusual. We report a case of cSCLC in a 78-year-old man
with no prior medical history who presented for evaluation of right upper lobe (RUL) lung mass. A CT scan
showed a 3.0 × 2.5 × 2.3 cm RUL lung mass with mildly prominent mediastinal and hilar lymphadenopathy. A
right thoracotomy with right upper lobectomy and lymphadenectomy was performed. Histological examination
and immunohistochemical stains conﬁrmed the diagnosis of combined small cell lung carcinoma (SCLC)with ad-
enocarcinoma (AC) and squamous cell carcinoma (SCC) components.
While there are available guidelines for treating SCLC, the optimal treatment for cSCLC which will improve prog-
nosis has not been adequately determined. We report a very rare category of primary lung malignant neoplasm
to represent our institution's experience in diagnosing and managing this type of rare case.
© 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Combined small cell lung cancer (cSCLC) is rare and comprises about
2–14% of small cell lung cancer (SCLC) cases [1,2]. According to World
Health Organization (WHO), cSCLC is considered as a lung cancer that
has small cell lung carcinoma (SCLC) component admixed with one
(or more) components of non-small cell lung carcinoma (NSCLC) [3].
The NSCLC component can be represented by AC, SCC, and large cell
neuroendocrine carcinoma (LCNEC). Most of the cases are SCLCwith ei-
ther adenocarcinoma or SCC component; however there are also rare
case reports of up to 3–4 different morphologic tumors which have
been reported [4,5]. SCLC in general, is the most aggressive of major
lung cancer types, with the worst long term prognosis and survival
rates [6]. It is recommended that if a tumor is composed of more than
one histological pattern and is found to contain any proportion of
SCLC cells to be classiﬁed as cSCLC, regardless of component is predom-
inantly seen in the mass [7].
The histogenesis of cSCLC appears to be complex. Wagner PL et al.
suggested that themorphological deviation of the components happens
when a SCLC-like cell is converted into a cell with the probability to de-
velop NSCLC features. Daughter cells of this trans-differentiated SCLC-
like cell then repeatedly divide and, under both internal and external
cell environmental effects, they obtain some mutations [4]. However,
the simultaneous appearance of both SCLC and other unrelated separate
primary histological variants is controversial [8,9].c. This is an open access article under
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Our patient is a 78-year-old male who had smoked 2–3 packs of cig-
arettes per day for approximately 35 years. He was referred to Mofﬁtt
Cancer Center for evaluation of right upper lobe (RUL) lung mass. The
patient ﬁrst began to have productive cough in the summer but he de-
nied hemoptysis. He attributed this change to increased amounts of
dust at work and did not seek evaluation until August 2014. A CT scan
was obtained which showed a 3.0 × 2.3 × 2.5 cm RUL lung mass with
mildly prominent mediastinal and hilar lymphadenopathy (Fig. 1).
He had a follow-up CT scan of the chest, performed on October 2014
which did not show any changes. PET scan was performed on October
2014 which revealed a 2.7 cm RUL nodule that corresponded to the
mass seen on CT scan.
His review of systems was within normal limits. His father died at
age 89 from an unknown type of metastatic cancer. His brain MRI was
negative for metastatic disease. All these ﬁndings had been discussed
with the patient and hewas given the option to proceedwith lung biop-
sy to establish a diagnosis with the small chance of a non-diagnostic bi-
opsy versus proceeding with right upper lobectomy and
lymphadenectomy. Given the size and location of the hilar lymph
node, robotic surgery was not advised due to the risk of injury to the
pulmonary artery. The patient elected to proceed with right thoracoto-
my with right upper lobectomy, intercostal muscle ﬂap, and
lymphadenectomy.the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
l cell lung cancer with adenocarcinoma and squamous cell carcinoma,
5.002
Fig. 1. Chest CT scan shows a 3.0 × 2.3 × 2.5 cm RUL lung mass.
2 S. AL Diffalha et al. / Human Pathology: Case Reports xxx (2015) xxx–xxxThe main surgical specimen consisted of upper lobe of right lung
measuring 14.5 × 8.5 × 6 cm, weighing 245 g. The visceral pleura of
the lobe was variegated, pink-tan to dusky red, and reveals an irregular,
retracted area on the lateral posterior aspect of the lobe measuring
1.5 cm in greatest dimension (inked in black). The remaining visceral
pleura was smooth and glistening. The posterior medial aspect of the
lobe revealed an irregular, ill-deﬁned, rubbery intraparenchymal
tumor which measured 3.5 × 3.5 × 2.8 cm. The tumor did not appear
to extend through the overlying visceral pleura. Neither bronchi nor
blood vessels were grossly involved by the tumor. The cut surface of
the tumor was variegated, tan-gray to pink, focally hemorrhagic and
areas of necrosis occupied less than 20% of the tumor. The remainder
of the pulmonary parenchymawas dark red, congested, and no satellite
nodules were grossly appreciated.
The representative sections of the tumor showed approximately 90%
adenosquamous carcinoma and 10% small cell carcinoma conﬁned to
the subpleural area. The lymph nodes show extensive involvement by
small cell carcinoma, with a focus of adenocarcinoma involving level
11 lymph nodes.
A large panel of immunohistochemical stains was performed. The
squamous cell carcinoma component was positive for AE1/AE3/CAM
5.2, CK7, CK5/6, and P40. The adenocarcinoma component was positive
for AE1/AE3/CAM 5.2, CK7, TTF-1, Napsin A and focally positive for
synaptophysin and chromogranin. The small cell component was
positive for AE1/AE3/CAM 5.2, CK7, CD56 and weakly positive for
synaptophysin. The tumor was negative for CK20 (Fig. 2). Manual
morphometric analysis showed 99% of small cell carcinoma cells to be
positive for Ki-67. Next Generation Sequencing (NGS) was performed;
however, it did not identify any clinically relevant results.3. Discussion
The case that we are presenting here has two challenges; ﬁrst is the
difﬁculty in establishing a preoperative diagnosis of these three compo-
nents if the patient underwent FNA or core biopsy.Wemay encounter a
diagnostic dilemma during evaluating cytology specimens which could
be prepared from this tumor site. In our case there was no cytology or
core biopsy performed before the surgery, but that will be an important
diagnostic challenge and pitfall. The needle may be sampling only one
component (SCC, AC or SCLC) or two components or all three of them
together. Most often we classify the lung primary carcinoma as SCLC
and NSCLC (SCC or AC). However we might not think that there are
two or three components present, since it is rare. As we know that
based on that diagnosis, the next step in managing the patient may be
different. If the cytology is reporting only SCC or AC components, thenPlease cite this article as: S. AL Diffalha, et al., Rare case of combined smal
Human Path Case Reports (2015), http://dx.doi.org/10.1016/j.ehpc.2016.0the patient will undergo surgery with or without chemo and radiation
therapy or neoadjuvant chemotherapy based on the updated
American College of Clinical Pharmacology (ACCP) guidelines for treat-
ment of clinical stages I and II NSCLC or no surgery for clinical stage III or
IV. On the other hand, surgerywill not be an option anymore if the diag-
nosis is SCLC on the cytology or the core biopsy. Unfortunately, litera-
ture has shown that cSCLC may often be resistant to chemotherapy
because of the NSCLC component [4,10].
Although, our case did not show any molecular signature by next
generation sequencing, it is considered a good practice to reach the
exact classiﬁcation of lung cancer in view of the fact that different
types of lungmalignancies have different biological and clinical proper-
ties and response to treatment [11,12]. It is recommended to perform
genetic testing (EGFR and ALK) on all NSCLC for the purpose of selecting
the targeted therapy according to the Association of Molecular patholo-
gy (AMP), College of American College (CAP) and the International As-
sociation for the Study of Lung Cancer (IASLC). As it is known that
EGFR and ALK are by far have the most published and data based evi-
dence in determining the treatment. For example if the patient with
NSCLC has an EGFRmutation generally responds to erlotinib, however,
crizotinib can be used if ALKmutation is present. It is important tomen-
tion that while EGFR mutations are very rare in SCLC, they are quiet
common (about 15–20%) in cSCLC, usually in nonsmoking females
who have AC component. KRAS also has important therapeutic input
in which is excluding therapy.
It has been reported that cSCLC shows reactivity to estrogen receptor
and/or progesterone receptor using immunohistochemical stains in a
about 50–67% of cases, despite that there is no available data yet if
that plays any rule in the prognosis and patient treatment [13]. In gen-
eral, patients with cSCLC have poor prognosis similar to patients with
SCLC [14].
We know that there are available guidelines for treating SCLC as a
single tumor [15], but in our casewe are facing unusual SCLCwith addi-
tional AC and SCC components. The optimal treatment for cSCLC which
will improve prognosis has not been adequately determined.
A few studies in the literature suggest surgical resection for the very
early stage cSCLC which might improve the patient's outcome [16]. An-
other approach is to start chemotherapy (CT) and/or radiation therapy
(RT), followed by surgical intervention for the residual NSCLC compo-
nents [17]. The long term prognosis of cSCLC patients is determined
by the SCLC component; it may be even show worse prognosis than
that of pure SCLC because it is more resistant to therapy [2,18].
Our patient was referred to the thoracic clinic for further treatment
recommendations. Since no molecular abnormalities were identiﬁed
by next generation sequencing, he received 3 cycles of cisplatin/
etoposide every 3weeks, with thoracic radiation over 35 fractions, com-
pleted in April 2015. His treatment course was complicated by admis-
sion for neutropenic fever with sepsis, after which he was discharged
home in a stable condition. His last visit was in December 2015, when
he complained of productive cough associated with low-grade fevers,
dyspnea and dysphagia. His prior chest CT-scans, as well as his most re-
cent one showed changes consistent with prior radiation effects on the
right side and focal consolidationwhich given his dysphasia historywas
concerning for aspiration. In addition, there were changes suggestive of
pulmonary ﬁbrosis seen on his scan fromMay 2015. These changes had
progressed on his most recent scan but there was no discrete evidence
of disease recurrence or progression on all his CT scans.4. Conclusion
Combined tumors in any organ site raise interesting biologic ques-
tions about the pathogenesis and relationship of the individual compo-
nents. Moreover, an accurate understanding of cSCLCs is of great
practical importance because treatment strategies are signiﬁcantly dif-
ferent for NSCLC and SCLC.l cell lung cancer with adenocarcinoma and squamous cell carcinoma,
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Fig. 2.TheH&E sections of the tumor shows approximately 90% adenosquamous carcinoma and10% small cell carcinoma, conﬁned to the subpleural area (A–D). The squamous component
is positive for AE1/AE3/CAM 5.2, CK7, CK5/6, and P40. The adenocarcinoma component is positive for AE1/AE3/CAM 5.2, CK7, TTF-1, and Napsin A and focally positive for synaptophysin
and chromogranin. The small cell component is positive for AE1/AE3/CAM 5.2 and CD56. The tumor is negative for CK20. Manual morphometric analysis shows 99% small cell carcinoma
cells positive for Ki-67.
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